Order Article Reprints

Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, Mukasa A, Mitsuhara T, Goto T, Yamaguchi S, et al. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Current Oncology. 2021; 28(1):726-739. https://doi.org/10.3390/curroncol28010071

Fujii, Masazumi, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi, and et al. 2021. "Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma" Current Oncology 28, no. 1: 726-739. https://doi.org/10.3390/curroncol28010071

Fujii, M., Kobayakawa, M., Saito, K., Inano, A., Morita, A., Hasegawa, M., Mukasa, A., Mitsuhara, T., Goto, T., Yamaguchi, S., Tamiya, T., Nakatomi, H., Oya, S., Takahashi, F., Sato, T., Bakhit, M., & on behalf of the BeatNF2 Trial Investigators. (2021). Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Current Oncology, 28(1), 726-739. https://doi.org/10.3390/curroncol28010071